Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nation-Wide Retrospective Analysis of Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma: A Study from Korean Multiple Myeloma Working Party (KMM1913).
Shin HJ, Kim DY, Kim K, Min CK, Lee JJ, Mun YC, Lee WS, Lim SN, Kim JS, Moo JH, Kim DJ, Bang SM, Won JH, Jo JC, Koh YI. Shin HJ, et al. Among authors: kim dy, kim dj, kim js, kim k. Cancer Res Treat. 2024 Mar 4. doi: 10.4143/crt.2024.074. Online ahead of print. Cancer Res Treat. 2024. PMID: 38453275 Free article.
Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/ refractory multiple myeloma.
Cho HJ, Jo JC, Lee YJ, Lee MW, Kim DY, Shin HJ, Im SN, Lee JH, Bae SH, Do YR, Lee WS, Kim MK, Jung J, Lee JM, Kim JH, Baek DW, Sohn SK, Moon JH. Cho HJ, et al. Among authors: kim dy, kim mk, kim jh. Korean J Intern Med. 2023 Mar;38(2):238-247. doi: 10.3904/kjim.2022.183. Epub 2023 Jan 26. Korean J Intern Med. 2023. PMID: 36698051 Free PMC article.
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Qin S, et al. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.
Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia during R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma.
Kim DY, Nam J, Chung JS, Jeon BE, Lee JH, Jo JC, Kim SW, Shin HJ. Kim DY, et al. Among authors: kim sw. Cancer Res Treat. 2022 Oct;54(4):1256-1267. doi: 10.4143/crt.2021.944. Epub 2021 Dec 31. Cancer Res Treat. 2022. PMID: 34990523 Free PMC article.
Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma.
Cho HJ, Jo JC, Lee YJ, Lee MW, Kim DY, Shin HJ, Im SN, Lee JH, Bae SH, Do YR, Lee WS, Kim MK, Jung J, Lee JM, Kim JH, Baek DW, Sohn SK, Moon JH. Cho HJ, et al. Among authors: kim dy, kim mk, kim jh. Korean J Intern Med. 2023 Jul;38(4):578. doi: 10.3904/kjim.2022.183e. Epub 2023 Jun 9. Korean J Intern Med. 2023. PMID: 37291840 Free PMC article. No abstract available.
5,131 results